Berylliosis

A form of pneumoconiosis caused by inhaled rare metal BERYLLIUM or its soluble salts which are used in a wide variety of industry including alloys, ceramics, radiographic equipment, and vacuum tubes. Berylliosis is characterized by an acute inflammatory reaction in the upper airway leading to BRONCHIOLITIS; PULMONARY EDEMA; and pneumonia.

Also Known As:

Networked: 344 relevant articles (5 outcomes, 23 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Sarcoidosis (Schaumann Disease)
2.	Hypersensitivity (Allergy)
3.	Inflammation
4.	Chronic Granulomatous Disease
5.	Lung Diseases (Lung Disease)

Experts

1.	Maier, Lisa A: 35 articles (01/2015 - 06/2002)
2.	Fontenot, Andrew P: 32 articles (11/2014 - 11/2002)
3.	Newman, Lee S: 24 articles (04/2015 - 03/2002)
4.	Newman, L S: 17 articles (10/2011 - 02/2000)
5.	Schuler, Christine R: 16 articles (11/2014 - 06/2004)
6.	Kreiss, Kathleen: 16 articles (07/2013 - 06/2002)
7.	Mack, Douglas G: 14 articles (06/2014 - 04/2006)
8.	Maier, L A: 13 articles (12/2014 - 08/2000)
9.	Weston, Ainsley: 12 articles (10/2012 - 06/2002)
10.	Stefaniak, Aleksandr B: 11 articles (06/2012 - 05/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Berylliosis:

1.	BerylliumIBA 01/01/2003 - "Brush Wellman, the world's leading producer and supplier of beryllium products, has systematically hidden cases of beryllium disease that occurred below the threshold limit value (TLV) and lied about the efficacy of the TLV in published papers, lectures, reports to government agencies, and instructional materials prepared for customers and workers. " 03/01/2001 - "Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant." 07/01/2007 - "The aims of this study were to determine the relationship between CD57 expression, a marker of T-cell senescence, and severity of chronic beryllium disease (CBD) and to determine the phenotypic and functional characteristics that differentiate beryllium-specific CD4(+) T cells in lung and blood. " 04/01/2005 - "The goal of this study was to characterize activation pathways of beryllium-responsive bronchoalveolar lavage (BAL) CD4(+) T cells from chronic beryllium disease patients to identify possible therapeutic interventional strategies. " 10/01/2004 - "We recommend that the results of this study be used to target at-risk audiences for hazard communications intended to prevent beryllium sensitization and chronic beryllium disease."
2.	Adrenal Cortex Hormones (Corticosteroids)IBA 09/01/2008 - "Corticosteroids were beneficial in chronic beryllium disease. " 12/01/2009 - "Despite this limitation, it is prudent to remove patients with chronic beryllium disease from further exposure and consider treating progressive disease early with long-term corticosteroids. " 12/01/2004 - "Chronic beryllium disease (CBD) shares many of its characteristics with sarcoidosis and is often treated with corticosteroids. " 12/01/2009 - "The current mainstay of management of chronic beryllium disease involves cessation of beryllium exposure and use of systemic corticosteroids. "
3.	BESIBA 12/01/2014 - "Primary monocyte-derived DCs (moDCs) models were generated from Be non-exposed healthy volunteers as a non-sensitized cell model, while PBMCs from BeS (Be sensitized) and CBD (chronic beryllium disease) were used as disease models. " 08/01/2014 - "The potential effect of adjusting the interval for repeated intensive testing to detect chronic beryllium disease among persons with BeS was assessed with a Markov model. " 06/01/2007 - "The current occupational exposure limit (OEL) for beryllium has been in place for more than 50 years and was believed to be protective against chronic beryllium disease (CBD) until studies in the 1990s identified beryllium sensitization (BeS) and subclinical CBD in the absence of physical symptoms. " 11/01/2014 - "This study examined absence rates among US Department of Energy workers who had beryllium sensitization (BeS) or were diagnosed with chronic beryllium disease (CBD) compared with those of other workers. " 05/01/2012 - "Exposure-response relations for beryllium sensitization (BeS) and chronic beryllium disease (CBD) using aerosol mass concentration have been inconsistent, although process-related risks found in most studies suggest that exposure-dependent risks exist. "
4.	AntigensIBA 11/01/2011 - "CD4(+) T cells are responsible for the progressive lung damage seen in patients with chronic beryllium disease (CBD), a granulomatous lung disorder in which antigen-specific, T(H)1-type, cytokine-secreting T cells have been characterized. " 11/01/2003 - "The pathobiology of chronic beryllium disease (CBD) involves the major histocompatibility complex class II human leukocyte antigen (HLA). " 11/01/2003 - "Electrostatic potential on human leukocyte antigen: implications for putative mechanism of chronic beryllium disease." 09/01/2003 - "We studied this process in chronic beryllium disease, in which the frequency of antigen-specific CD4+ T cells in the lung is large and circulating antigen-specific cells are also detectable. " 07/01/1994 - "We conclude that the lymphocyte-predominant pulmonary inflammatory response in beryllium disease is related to the magnitude of the localized response to antigen and that BAL cellularity, differential cell count, and BeLT reflect beryllium disease clinical severity.(ABSTRACT TRUNCATED AT 250 WORDS)"
5.	HLA-DPB1 (HLA DPB1)IBA 10/15/2012 - "Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove." 07/01/2011 - "Our objective was to extend current knowledge of the genetics of beryllium disease by examining all HLA-DPB1 and HLA-DPR1 gene polymorphisms and the interactions between them. " 06/01/2009 - "Because inbred strains of mice have not provided good models of CBD to date, three strains of HLA-DPB1 transgenic mice in an FVB/N background were developed; each contains a single allele of HLA-DPB1 that confers a different magnitude of risk for chronic beryllium disease: HLA-DPB1*0401 (OR approximately 0.2), HLA-DPB1*0201 (OR approximately 3), and HLA-DPB1*1701 (OR approximately 46). " 12/01/2007 - "BTNL2 allele associations with chronic beryllium disease in HLA-DPB1*Glu69-negative individuals." 12/30/2005 - "Among the 40 HLA-DPB1 gene variants that code for E69, molecular epidemiological studies have suggested a risk hierarchy, where some variants appear to convey low to moderate risk of chronic beryllium disease (e.g., HLA-DPB1*0201, approximately 3-fold increased risk), some convey an intermediate risk (e.g., HLA-DPB1*1901, approximately 5-fold) and others convey high risk (e.g., HLA-DPB1*1701, >10-fold). "
6.	HLA-DP Antigens (HLA-DP)IBA 07/01/2001 - "Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP." 10/01/2005 - "The results of the blood Be-LPT, performed in a single laboratory on 165 subjects (86 Be-exposed controls, 38 Be-sensitized without lung granulomas and 41 berylliosis cases) identified at a single large Be production factory, were analyzed for their realtionship with the HLA-DPGlu69 status as determined by high resolution HLA-DP typing. " 06/10/2014 - "Susceptibility to chronic beryllium disease (CBD) is linked to certain HLA-DP molecules, including HLA-DP2. " 09/01/2009 - "Overall, these data support the proposal that HLA-DP high-affinity peptides might be used as a model for specific berylliosis therapy." 04/01/2005 - "These results indicate a prominent role for HLA-DP and LFA-1 in BAL CD4(+) T cell activation and further suggest that specific Abs to these molecules could serve as a possible therapy for chronic beryllium disease."
7.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/01/2007 - "The odds of chronic beryllium disease in the presence of at least one TNF-alpha-308*02 or TNF-alpha-238*02 allele was not significant (OR=1.0; 95% CI=0.7, 1.7 and OR=0.8; 95% CI=0.4, 1.6). " 08/21/2000 - "In vitro stimulation of bronchoalveolar lavage cells from patients with chronic beryllium disease (CBD) induces the production of TNF-alpha. " 05/01/1994 - "In patients with beryllium disease (n = 39), lavage fluid TNF-alpha concentration was higher than that of 16 normal subjects. " 04/01/2007 - "Unlike an earlier report, there was no association between these specific TNF-alpha alleles and either chronic beryllium disease or sensitization to beryllium." 04/01/2007 - "TNF-alpha polymorphisms in chronic beryllium disease and beryllium sensitization."
8.	beryllium oxideIBA 03/01/1983 - "[Studies on the effects of beryllium oxide in purity and fired temperature to the occurrence of chronic pulmonary berylliosis]." 07/01/2015 - "Pathological changes of the lung tissue in beryllium oxide exposure group rats were in line with the characteristics of beryllium disease in human. " 03/01/1983 - "Among various beryllium (Be) compounds, beryllium oxide (BeO) has so far been noted as a causative substance which introduce chronic pulmonary berylliosis. " 12/01/2008 - "We followed a cohort of 136 beryllium oxide ceramics workers from 1992 to 2003, including those who left employment, for beryllium sensitization and chronic beryllium disease (CBD). "
9.	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 07/01/1992 - "Serum angiotensin converting enzyme activity in chronic beryllium disease." 07/01/1992 - "Serum angiotensin converting enzyme (SACE) activity is used as a marker of sarcoidosis activity and severity, but in chronic beryllium disease (CBD) the studies of SACE give conflicting results. " 04/01/1999 - "To test the hypothesis that the angiotensin converting enzyme (ACE) genotype is associated with chronic beryllium disease (CBD) and disease severity, we studied 50 cases of CBD and compared their ACE genotype to that of two different control groups, consisting of: (1) 50 participants from a beryllium machining facility; and (2) 50 participants from a non-beryllium-associated workplace. "
10.	Nerve Growth Factor (NGF)IBA 11/01/2008 - "The aims of this study were to investigate the secreted levels of NGF in bronchoalveolar lavage fluid (BALF) from sarcoidosis patients compared with patients with resolved disease, patients with another granulomatous disease--chronic beryllium disease (CBD)--and healthy subjects and also to investigate the relationship between NGF levels and markers of inflammation. "

Therapies and Procedures

1.	Chelation Therapy (Therapy, Chelation) 01/01/2008 - "A routine method for the quantification of beryllium in biological fluids is essential for the development of a chelation therapy for Chronic Beryllium Disease (CBD). "
2.	X-Ray Film 05/01/1992 - "In the six baboons, conventional imaging techniques (chest x ray film, computed tomography scan, gallium scintigraphy), failed to show either any lung abnormality or mediastinal lymph nodes consistent with beryllium disease. " 05/01/1992 - "In conclusion, when compared with conventional techniques such as chest x ray film, computed tomography scan, magnetic resonance imaging, and gallium scintigraphy, J001X scintigraphy has proved its ability to detect occult lesions in experimental berylliosis in baboons. "
3.	Traction 05/01/1995 - "Chronic pulmonary berylliosis presents both in computed tomography, including high resolution techniques, and in plain radiographs of the chest with unspecific results: subpleural micronodular changes, thickening of interlobular septa, occurrence of intralobular septa, traction bronchiectasis, and honeycombing. "
4.	Surgical Instruments (Clip) 09/01/2009 - "Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells."
5.	Lasers (Laser) 08/01/1986 - "The value of laser ion mass analysis (LIMA) for the detection of beryllium disease in routine histological sections was investigated. " 08/01/1986 - "New aid for diagnosing chronic beryllium disease (CBD): laser ion mass analysis (LIMA)."